FDA OKs expanded use of Astellas and Pfizer’s Xtandi

Astellas Pharma (OTCPK:ALPMF) and development/commercialization partner Pfizer (NYSE:PFE) announce FDA approval of Xtandi (enzalutamide) for the treatment of men with metastatic castration-sensitive prostate cancer, a type of prostate cancer that affects ~40K Americans.

The androgen receptor inhibitor was approved in the U.S. in August 2012 for metastatic castration-resistant prostate cancer and in July 2018 for non-metastatic castration-resistant prostate cancer.

https://seekingalpha.com/news/3526667-fda-oks-expanded-use-of-astellas-and-pfizers-xtandi